title: Itopride therapy for functional dyspepsia: a meta-analysis.
abstract: OBJECTIVE
  To evaluate the therapeutic effects of itopride vs other drugs (placebo, domperidone, mosapride) for functional dyspepsia (FD).
  
  
  METHODS
  Randomized controlled trials (RCTs) of itopride for FD were retrieved from databases. Relevant information was extracted and analyzed, using the relative risk (RR) and weighted mean deviation, as appropriate. A random or fixed effect model was used, based on the heterogeneity of the included articles, and visual inspection of funnel plots was used to evaluate publication bias.
  
  
  RESULTS
  Nine RCTs enrolling 2620 FD cases were included; 1372 cases received itopride treatment and 1248 cases received placebo or other drugs (control groups). Compared with control groups, itopride had superior RR values of 1.11 [95%CI: (1.03, 1.19), P = 0.006], 1.21 [95%CI: (1.03, 1.44), P = 0.02], and 1.24 [95%CI: (1.01, 1.53), P = 0.04] for global patient assessment, postprandial fullness, and early satiety, respectively. For the Leeds Dyspepsia Questionnaire score, the weighted mean deviation was -1.38 [95%CI: (-1.75, -1.01), P < 0.01]. The incidence of adverse effects was similar in the itopride and control groups. The funnel plots for all indicators showed no evidence of publication bias.
  
  
  CONCLUSIONS
  Itopride has good efficacy in terms of global patients assessment, postprandial fullness, and early satiety in the treatment of patients with FD and shows a low rate of adverse reactions. Itopride can greatly improve FD syndromes-score.
authors: Department of Gastroenterology, The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou 310006, Zhejiang Province, China.
authors: Xuan
authors: X
authors: Huang
authors: Bin
authors: B
authors: Lv
authors: Shuo
authors: S
authors: Zhang
authors: Yi-Hong
authors: YH
authors: Fan
authors: Li-Na
authors: LN
authors: Meng
mesh_terms: D000932:Antiemetics / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use*; D001593:Benzyl Compounds / Q000627:therapeutic use*; D004294:Domperidone / Q000627:therapeutic use; D004415:Dyspepsia / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use; D019518:Postprandial Period; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D012527:Satiation; D016896:Treatment Outcome
chemical_list: D000932:Antiemetics; D001549:Benzamides; D001593:Benzyl Compounds; D005765:Gastrointestinal Agents; D009025:Morpholines; D004294:Domperidone; C102254:itopride; C062720:mosapride
keywords: Functional dyspepsia; Itopride; Meta-analysis; Prokinetic agents; Randomized controlled trials